Abstract: AbstractThe aggregation of α‐synuclein (α‐Syn) is a critical pathological hallmark of Parkinson's disease (PD). Prevention of α‐Syn aggregation has become a key strategy for treating PD. Recent studies have suggested that α‐Syn undergoes liquid‐liquid phase separation (LLPS) to facilitate nucleation and amyloid formation. Here, we examined the modulation of α‐Syn aggregation by myricetin, a polyhydroxyflavonol compound, under the conditions of LLPS. Unexpectedly, neither the initial morphology nor the phase‐separated fraction...
(read more)